Cure for what ails

23 January 2009 By Rob Cox

A Pfizer deal with Wyeth would illustrate the merits of merging when economies are slowing or shrinking. A deal done mostly in stock, slicing out padding in costs and R&D, would benefit both sets of shareholders. This looks like a taste of deals to come.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)